The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2133|178|2|571-571

ISSN: 0007-0963

Source: BRITISH JOURNAL OF DERMATOLOGY, Vol.178, Iss.2, 2018-02, pp. : 571-571

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next